What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio...
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 4.1% in the afternoon session after major indices including the S&P 500 and...
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p...
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 8.7% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated in January.
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of its fourth-quarter 2025 financial results, a move that signals investor confidence in the company’s radical transformation. Once teetering on the edge of a [...]
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its non-GAAP profit of $0.11 per share was significantly above analysts’ consensus estimates.
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported fourth-quarter financial results that significantly beat analyst expectations. Novavax announced revenue of $147.1 million, up approximately 67% from the prior year's quarter and well ahead of forecasts. The company also posted a surprise profit with earnings per share (EPS) of $0.11. This was a significant beat, as analysts had expected a loss of $0.49 per share, and it marked a notable turnaround from a loss of $0.51 per share in the same period of the previous year. The strong top-line growth and unexpected profitability drove investor optimism.
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 per share was significantly above analysts’ consensus estimates.
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.
